Every treatment plan is personalized based on a child's medical history, metabolic health, growth, and long-term goals
Exenatide generally provided a similar A1c reduction to long-acting insulin glargine in one study, but with weight loss instead of weight gain ( [102] )
To determine therapeutic approaches and targets for diabetes management, patient characteristics, functional status, comorbidities and overall care plan will need to be considered
The FDA has warned that unapproved versions of GLP-1 drugs, including compounded semaglutide and tirzepatide, do not undergo FDA review for safety, effectiveness, or quality before being marketed, and that patients may face risks from products that have not been tested in large-scale clinical trials